0000000000824528

AUTHOR

Alise Gramatniece

showing 1 related works from this author

Erratum for Yahav et al., "New β-Lactam-β-Lactamase Inhibitor Combinations".

2021

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa. Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, a…

0301 basic medicineMicrobiology (medical)General Immunology and MicrobiologyCarbapenem resistantbiologyEpidemiologyChemistryStereochemistryKlebsiella pneumoniae030106 microbiologyPublic Health Environmental and Occupational HealthReviewbiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycoses03 medical and health scienceschemistry.chemical_compound030104 developmental biologyInfectious Diseasesβ lactamase inhibitorLactampolycyclic compoundsbacteriaClinical microbiology reviews
researchProduct